ClinicalTrials.gg
Active, not recruitingNCT03465618Updated May 1, 2026

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

A Phase 1 interventional study of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging and Blood and Urine samples in Brain Cancer and Pituitary Adenoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Primary conditionPituitary NeoplasmsRegistry: Brain NeoplasmsReclassifiedWhy we changed it
Registry
Brain Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pituitary Neoplasms
Why
  1. The study's listed conditions name Pituitary Neoplasms, a narrower term within Brain Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Pituitary Neoplasms with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Pituitary Neoplasms · United States.

Enrollment
30th of 45
17 · median 40
Started
2018
the only one that year
Phase 1
11 of 68
3 open now
Primary completion
2027-03
later than 6 of 15 live
Registered
49th of 68
by date
Lead sponsor
3 of 68
Memorial Sloan Kettering Cancer Center

Among the 68 studies in Pituitary Neoplasms with a site in United States, this one is the 30th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2018, is one of 11 in phase 1, reaches primary completion later than 6 of the 15 other live ones, and was the 49th registered.

Pituitary Neoplasms

200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.

Browse Pituitary Neoplasms studies →

Open to participants now

15 of the 68 studies in Pituitary Neoplasms with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Pituitary Neoplasms studies recruiting now, 14 (39%) set no upper age limit and 10 (28%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pituitary Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test if PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles, can be used to take pictures of brain tumors. The investigators want to understand how the particles are distributed and removed from the body, which may help others be treated in the future. This will be the first time that 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles are being used in people. The amount of particles given in this study is very small compared to the amount that was used in mice animal studies.

03

Conditions studied

  • Brain Cancer
  • Pituitary Adenoma

Browse trials for

Keywords

  • 89Zr-cRGDY Ultrasmall Silica Particle Tracers
  • Pet Scan
  • 17-599
04

In context

Pituitary Neoplasms Reclassified

200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.

This study's enrollment of 17 is below the median of 60 across 121 interventional studies indexed under Pituitary Neoplasms.

Browse Pituitary Neoplasms studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Pituitary Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • confirmed diagnosis of malignant primary brain tumor clinical and radiographic findings consistent with a pituitary adenoma, or known cancer with brain lesion presumed to be metastatic.
  • Normal baseline cardiac function based upon pre-operative evaluation at the physcian's discretion
  • All patients of childbearing age must use an acceptable form of
  • Women who are pre-menopausal must have a negative serum pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Known pregnancy or breast-feeding Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer

    °This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or Classification III or IV heart disease

  • More than one cancer active in the last 5 years
  • Active metastatic cancer in addition to malignant primary brain tumor
  • Weight greater than the 400-lb weight limit of the PET scanner
  • Unmanageable claustrophobia
  • Inability to lie in the scanner for 30 minutes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    surgical patients

    Patients will be i.v. injected with approximately 5 mCi (\~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans may be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.

    Drug: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging · Other: Blood and Urine samples

  • Experimental
    non-surgical patients

    Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (\~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging

    Drug: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging · Other: Blood and Urine samples

Interventions

  • Drug89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging

    A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.

  • OtherBlood and Urine samples

    Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan

07

What researchers measure

Primary outcomes

  1. distribution within these high-grade gliomas

    using serial PET imaging and/or correlative histologyFollowing tumor biopsy or surgical resection, histologic assessments will be performed using autoradiography to visualize the distribution of this agent within tumor tissue specimens.

    Time frame: 2 years

08

Study locations

1 site
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2018 (actual). Primary completion is estimated for Mar 2027, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 14, 2018
StartActual
Mar 7, 2018
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03465618
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Mar 7, 2018
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 1, 2026

Study contacts

Nelson Moss, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion